Kelun-Biotech's 2025 Annual Results Showcase Successful Product Launches and Promising Future

Kelun-Biotech 2025 Annual Results Overview

Kelun-Biotech, a leading biopharmaceutical company, has recently published its audited consolidated results for the year that ended on December 31, 2025. In the report, the company announced a remarkable total revenue of approximately RMB 2,057.92 million, alongside a gross profit of about RMB 1,478.78 million. This represents significant year-on-year growth, underlining the company's strong market performance.

Despite recording a loss of RMB 381.97 million during the reporting period, the adjusted annual loss was notably less at approximately RMB 211.28 million. The company's financial health remains robust, with cash and financial assets totaling around RMB 4,559.36 million and a low debt-to-asset ratio of just 18.7%. These figures suggest that Kelun-Biotech has ample financial resources to continue its operations and drive further growth.

Key Achievements and Product Launches

In 2025, Kelun-Biotech leveraged its proprietary OptiDC™ technology platform to deepen its foothold in the antibody-drug conjugate (ADC) and new drug delivery systems. The company has successfully commercialized four key products, with eight indications approved for marketing in China. These include:

1. Sacituzumab Tirumotecan (佳泰莱®) - Approved for treating adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
2. Trastuzumab Botidotin (舒泰莱®) - Approved for adult patients with HER2+ breast cancer who have previously undergone anti-HER2 therapies.
3. Tagitanlimab (科泰莱®) - Gained approval for treating nasopharyngeal carcinoma (NPC) in combination with chemotherapies.
4. Cetuximab N01 (达泰莱®) - Approved for use in the treatment of metastatic colorectal carcinoma (mCRC).

These products reflect the company’s commitment to addressing unmet medical needs and expanding its portfolio across various therapeutic areas.

Advancing Innovative Therapeutics

Kelun-Biotech's ambitious R&D pipeline currently boasts more than 30 drug candidates, with over 10 actively in clinical stages. The company is focusing not only on oncology treatments but is also targeting autoimmune diseases and metabolic disorders for future expansions. This diversification is expected to enhance the company’s global competitive edge.

The gradual expansion of indications has also been a key highlight. The company received approvals to market sac-TMT in a diverse array of cancer types, bolstered by positive results from Phase 3 studies presented at major international oncology conferences.

Future Prospects and Strategic Focus

Looking ahead, Kelun-Biotech aims to strengthen its innovation pipeline by optimizing its payload technologies and expanding its applications into non-oncology disease areas. The strategic focus for 2026 will include the continuation of robust drug development and the commercialization process, bolstered by enhancing global collaboration opportunities with partners such as MSD and Ellipses Pharma.

Moreover, the company is poised to implement strategies adapting to global market demands by potentially launching its products in overseas markets. Kelun-Biotech remains highly committed to improving operational systems that will position them as a leading biopharmaceutical firm on the global stage.

Sustaining Growth Through ESG Initiatives

Kelun-Biotech has also placed a strong emphasis on environmental, social, and governance (ESG) considerations as part of its operational framework. The firm's initiatives have led to recognition for outstanding ESG performance and contributions toward sustainable development.

As the market evolves, Kelun-Biotech looks set to emerge as a front-runner in the biopharmaceutical industry by marrying innovative drug development with economic and social responsibility.

In summary, Kelun-Biotech's impressive annual results mark a turning point for the company. As it navigates the challenges of the biopharmaceutical landscape, its emphasis on innovation, broadening its therapeutic scope, and harnessing strategic partnerships are likely to contribute significantly to its future success.